Vol. 18/No. 14 | OncologyLive

Novel Therapy Partners Emerge in Melanoma Research

July 18, 2017

A novel combination therapy aimed at 2 processes implicated in NRAS-mutant melanoma has displayed promising activity in preclinical investigations, signaling an avenue of exploration for a new therapeutic approach for patients who currently have few options.

Myeloma Trial Explores Optimal Induction, Maintenance Regimens

July 17, 2017

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

Beyond Tumor Type: New Milestones on a Long Road

July 16, 2017

After years of efforts to steer clinical trials toward molecularly defined therapeutic targets, oncology researchers recently notched 2 key successes in changing the paradigm of how patients with advanced cancers are diagnosed and treated.

Debate Over Randomized Trials: Necessary Versus Optional

July 14, 2017

In the ongoing debate regarding the role of randomized trials in defining the standard of care in cancer management, adherents of this so-called gold standard acknowledge the problems associated with conclusions drawn from prospective nonrandomized studies or retrospective analyses of patients managed with different approaches.